Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing ...

Discussions between Novo Nordisk and the Novo Nordisk Foundation that controls the company regarding a CEO change have been ...

Novo Nordisk NVO announced a significant partnership with Septerna SEPN, a U.S.-based biotech company, valued at up to $2.2 billion, to tap the growing obesity treatment market. F ...

European stock markets hovered around the flatline on Monday, as investors gauged potential trade negotiations between the ...

Investing.com -- Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy.

Novo Nordisk said the Food and Drug Administration has accepted its submission of a new drug application for a Wegovy pill to treat obesity. The Bagsvaerd, Denmark, company said Friday that if the ...

Partnerships, especially with Novo Nordisk for GLP-1 weight-loss drugs ... Management forecasts $2.3–$2.4 billion in revenue for 2025, implying nearly 60% growth at the midpoint, driven in ...

The move is part of a new partnership between Caremark and Wegovy's manufacturer, Novo Nordisk, according to CVS' first-quarter earnings release. Caremark will also drop the weight loss drug ...